Hinokiflavone

Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC₅₀ value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity^[1][2][3]. In Vitro:Hinokiflavone (500 μM, 90 min) inhibits splicing of the adenovirus and the HPV18E6 pre-mRNAs, showed a stronger effect on pre-mRNA splicing than Isoginkgetin (HY-N2117) in vitro^[1].
Hinokiflavone (0-30 μM, 24 h) induces either cell cycle arrest or eventual cell death and increases levels of SUMOylated proteins by inhibiting sentrin-specific protease 1 (SENP1) activity in HEK 293 cells^[1].
Hinokiflavone (0-40 μM, 24 h) suppresses colorectal tumor cell proliferation, cell migration and invasion ability but promotes cell Apoptosis via the mitochondria-mediated apoptotic pathway^[2].
Hinokiflavone (0-128 μg/mL, 24 h) reduces the expression of virulence factors in staphylococcus aureus by directly interacting with caseinolytic protease P (ClpP)^[3].
In Vivo:Hinokiflavone (25 or 50 mg/kg, i.p., daily for 24 days) has antitumor activity via suppressing tumor proliferation, metastasis and inducing Apoptosis in CT26 tumor-bearing mice^[2].
Hinokiflavone (100 mg/kg, s.c., every 12 h for 96 h) shows a protective effect on pneumonia infection by Improving survival rate in mice^[3].